GT Medical Technologies

Executive Summary

GT Medical Technologies is a private company pioneering a novel approach to brain tumor treatment with its GammaTile therapy. GammaTile is a surgically targeted radiation therapy that delivers immediate, localized radiation at the time of tumor removal, eliminating the need for post-surgical daily radiation sessions. This innovation addresses a critical unmet need in neuro-oncology by reducing treatment delays and improving patient convenience. The company's technology has received FDA clearance and is being adopted at leading neurosurgical centers. With a strong focus on improving outcomes for patients with brain tumors, GT Medical is well-positioned to capture a significant share of the brain tumor radiation market, which is estimated to exceed $1 billion annually. The company's unique value proposition—immediate therapy initiation and reduced treatment burden—differentiates it from traditional external beam radiation and brachytherapy options. While early in its commercial trajectory, GT Medical has demonstrated clinical utility and growing adoption, supported by positive real-world evidence. The company's private status allows it to focus on long-term value creation without quarterly earnings pressure.

Upcoming Catalysts (preview)

• Q4 2026Publication of expanded clinical data from post-market surveillance for new indications (e.g., recurrent glioblastoma)70% success
• Q1 2027Potential Medicare reimbursement expansion for GammaTile procedure60% success
• Q3 2026Strategic partnership or distribution agreement for international market entry50% success